Empowered Funds LLC Buys Shares of 25,667 Sotera Health (NASDAQ:SHC)

Empowered Funds LLC bought a new stake in Sotera Health (NASDAQ:SHC) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 25,667 shares of the company’s stock, valued at approximately $351,000.

A number of other hedge funds have also made changes to their positions in the stock. Blue Trust Inc. grew its stake in Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after purchasing an additional 1,140 shares in the last quarter. True Wealth Design LLC acquired a new position in Sotera Health in the third quarter worth approximately $32,000. GAMMA Investing LLC raised its position in Sotera Health by 37.5% during the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock valued at $56,000 after acquiring an additional 1,121 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in Sotera Health in the third quarter worth approximately $91,000. Finally, SG Americas Securities LLC acquired a new position in shares of Sotera Health during the 3rd quarter worth $163,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Sotera Health Trading Down 0.8 %

Shares of NASDAQ:SHC opened at $13.52 on Friday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The stock’s 50-day moving average is $13.45 and its 200-day moving average is $14.56. The company has a market cap of $3.83 billion, a P/E ratio of 54.08 and a beta of 1.91. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44.

Wall Street Analysts Forecast Growth

SHC has been the subject of a number of recent research reports. Citigroup upped their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a research report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Sotera Health in a report on Friday, December 6th. They set a “neutral” rating and a $14.00 price objective on the stock. Finally, Barclays reduced their target price on Sotera Health from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Sotera Health currently has a consensus rating of “Moderate Buy” and an average target price of $16.08.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.